What are your top takeaways from SGO 2026?

A pivotal theme of SGO 2026 was the dramatic rise in ADCs in every gynecologic cancer, from front-line to recurrent disease. Along with notable updates for several studies, data from others were treatment-defining. (1)

The following studies were selected for further review.

Ovarian Cancer: Low-grade s...

The top presentations for me were the KEYNOTE-B96 and the ROSELLA trials. In that same session, there was another abstract presented on cadonilimab bispecific antibody for IO therapy (international group; one of the authors, Yang Sun).